Covalon Reports Fifth Consecutive Quarter of Positive Earnings
Year-To-Date Revenue Grew 21% and Year-To-Date Adjusted EBITDA Increased by 57%
MISSISSAUGA, Ontario, May 28, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 second quarter results for the period ended March 31, 2025, along with a number of important recent achievements and highlights.
Brent Ashton, Covalon's Chief Executive Officer, reported, "In the past few months, the Covalon team has delivered on several of our key priorities that have led to expanded sales with new and existing customers, new agreements with key strategic partners, and exciting new clinical evidence generation.
In the first six months of our 2025 fiscal year, Covalon has:
Grown revenue by 21%,
Grown Gross Profit by 12%
Reduced Operating Expenses by 8%
Increased Adjusted EBITDA by 57%
As stated last quarter, we fully anticipated our U.S. Advanced Wound Care sales channel to have a sequential quarter decline in Q2. This is not consequential, as we have a clear line of sight via in-house orders, forecasts and recent strategic partner sell out trends, to a strong Q3 and second half.
Covalon recently signed a major distribution agreement with our longstanding strategic partner, Paul Hartmann USA, for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings. Covalon's U.S. Advanced Wound Care sales channel has been an important growth driver for the Company, and our first half of FY'25 was double the revenue from the same period two years ago.
Our U.S. Vascular Access and Surgical Consumables sales channel had excellent sequential quarterly growth of 19%, and year to date is up 46% vs. the prior year, led by significant growth from Covalon's VALGuard® Vascular Access Line Guard product. New clinical evidence on Covalon's VALGuard® will be presented at two prestigious scientific meetings in the fall and is advancing through the publication process in a major, well-regarded academic journal. This will be a significant accelerator to the surge in adoption that we have seen with major U.S. hospitals.
We have also made significant headway in our International sales channel, and our Q2 revenue of $2.3 million marked our highest quarterly revenue for International in more than five years, and has grown 44% year to date.
In a volatile and complex global trade environment, Covalon's North American-centric manufacturing strategy has yielded no tariff-related costs to date, and the Company sees the current tariff environment as a competitive advantage.
Covalon is in a stronger position than it has ever been, with profitable operations and a clean balance sheet with more than $18 million in cash and no debt. We have retained a highly regarded financial and strategic advisor to identify merger and acquisition opportunities and unlock value for all shareholders. Our accelerated focus on market development is generating exciting results. I see a clear path for Covalon to become a major player in the lucrative healthcare spaces we operate in."
Q2 FY'25 Financial Highlights
Revenue of $7.6 million led by strong growth in the U.S. Vascular Access and Surgical Consumables business as well as the International business
Adjusted EBITDA of $0.6 million – Covalon's 5th consecutive quarter of profitability
Strong free cash flow generation of $0.6 million
Recent Covalon Achievements and Highlights
Exciting results from an impactful clinical evidence study by a nursing research team at a large United States children's hospital have been selected for presentation at two prestigious scientific meetings this fall and are advancing through the final stages of the publication process in a major, well-regarded academic journal. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Announces-Exciting-New-Clinical-Research-Evaluating-VALGuard-Vascular-Access-Line-Guard/default.aspx
Signed a new distribution agreement with longstanding strategic partner Paul Hartmann USA for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings.
The Company initiated work with Origin Merchant Partners to pursue strategic options to maximize shareholder value and expand the reach of our innovative medical technologies. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Retains-Financial-and-Strategic-Advisor-to-Advise-on-Shareholder-Value-Enhancing-Opportunities/default.aspx
Promoted Kim Crooks to be Chief Operating Officer and join Covalon's Board of Directors. Promoted Dr. Kate Evely to be Vice President of Clinical Affairs. Both Ms. Crooks and Dr. Evely have been instrumental in the recent success of the company. Ms. Crooks' announcement can be found athttps://ir.covalon.com/news/news-details/2025/Covalon-Announces-Promotion-of-Kim-Crooks-to-Chief-Operating-Officer-and-Appointment-to-Board-of-Directors/default.aspx
Successful investor presentations and meetings at Planet Microcap Showcase: Vegas 2025 and the 2025 Bloom Burton Healthcare Investor Conference. Presentation content and audio can be found here:https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/guest_book?session_id=HcJChMRczMNFyjGQ8jTLb3
The Company has successfully navigated the volatile global tariff environment with no additional tariff-related costs in Q2, FY'25. Based on the current tariff environment, Covalon does not anticipate any material future tariff costs related to the 2025 tariff changes. As the largest North American manufacturer of collagen wound care dressings, the Company sees the current tariff environment as a competitive advantage for its U.S. Advanced Wound Care business.
Conference Call Scheduled
A conference call and webcast to discuss Covalon's fiscal 2025 Q2 financial results will be held on Wednesday, May 28 at 8:30am Eastern Time. To view, listen to, and participate in the live webcast, please follow the link below:
https://events.q4inc.com/attendee/971812521
To listen and participate via the conference call, please dial:
North American Toll-Free: 1-800-549-8228Local (Toronto): 289-819-1520Local (New York): 646-564-2877Conference ID: 92114
Participants will be able to ask questions of Company management during the Q&A portion of the conference call.
A recording of the call will also be available on www.covalon.com under Financials on the Investors tab.
Q2 Financial Overview
For the three-month period ending March 31, 2025:
Total revenue decreased to $7,585,968 compared to $8,388,022 in the same period of the prior year. The decrease in product revenue was primarily driven by a normalization of channel inventory for one of the Company's Advanced Wound Care U.S. strategic partners.
The Company reported a gross margin of 55% for the period, compared to 63% in the same period of the prior year. The year-over-year decrease in gross margin was primarily driven by changes in geographic and product mix.
The operating expenses were relatively consistent at $3,857,686, compared to $3,827,704 in the same period of the prior period.
The operations department covers expenses related to quality control, quality assurance, production, and regulatory activities. Operations expenses increased slightly to $451,471 compared to $423,239 in the same period of the prior year. This increase was primarily due to higher employee training costs incurred in the current period, which helped to strengthen operational efficiency and compliance with regulatory standards.
Research and development expenses decreased to $320,459 compared to $450,510 in the same period of the prior year primarily due to lower patent & trademark costs as the costs can vary by quarter and fiscal year due to the timing and region of the renewals.
Sales and marketing expenses were flat at $1,250,162, compared to $1,262,960 in the same period of the prior year. The Company continues to optimize sales and marketing strategies to accelerate demand for the company's products.
General and administrative expenses increased to $1,835,594 compared to $1,690,995 in the same period of the prior year, reflecting higher professional service fees. Wages, benefits, and consulting fees (for all departments) included non-cash share-based compensation expenses of $65,540, down from $81,464 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
For the six-month period ending March 31, 2024:
Total revenue increased to $15,751,948 compared to $13,076,667 in the same period of the prior year, with double digit growth in the 3 main sales channels the company is focused on – the U.S. Advanced Wound Care sales channel, the U.S. Vascular Access and Surgical Consumables sales channel and the International sales channel.
Gross Margin decreased to 58% compared to 62% in the same period for the prior year. During the six months ended March 31, 2025, the Company recorded a $114,645 release in inventory provision due to revised obsolescence estimates, compared to an inventory provision of $482,095 recorded during the six months ended March 31, 2024. Gross margin fluctuates as a result of the mix of products sold in any given quarter, or year, by product type and geography.
Operating expenses decreased to $7,537,484 compared to $8,147,756 in the same period of the prior year. The majority of this decrease, is attributable to reduced sales and marketing expenses. Additional spending reductions were realized across operations, research and development, and general and administrative functions, reflecting the Company's continued focus on cost efficiency and disciplined expense management.
Operations expenses decreased to $822,540 from $1,053,952 in the same period of the prior year. The reduction was primarily attributable to the timing of expenses related to product development initiatives that were recognized in the prior year.
Research and development expenses decreased to $693,798 compared to $761,921 in the same period for the prior year, mainly due to lower patent and trademark costs.
Sales and marketing costs decreased to $2,459,982 compared to $2,909,263 in the same period of the prior year, due primarily to lower staffing levels.
General and administrative expenses increased to $3,561,164 compared to $3,422,620 in the same period in the prior year, due primarily to higher spending on professional service fees.
Wages, benefits, and consulting fees (for all departments) include a non-cash compensation expense of $156,063, down from $197,393 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
Statement of Operations
The following audited table presents Covalon's consolidated statements of operations for the three-month and six-month periods ended March 31, 2025, and 2024.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Revenue
Product
$7,585,968
$8,388,022
$15,663,908
$12,963,789
Development and consulting services
-
-
5,826
56,640
Licensing and royalty fees
-
25,588
82,214
56,238
Total revenue
7,585,968
8,413,610
15,751,948
13,076,667
Cost of sales
3,446,462
3,103,148
6,617,976
4,917,668
Gross profit
4,139,506
5,310,462
9,133,972
8,158,999
Operating expenses
Operations
451,471
423,239
822,540
1,053,952
Research and development activities
320,459
450,510
693,798
761,921
Sales, marketing and agency fees
1,250,162
1,262,960
2,459,982
2,909,263
General and administrative
1,835,594
1,690,995
3,561,164
3,422,620
3,857,686
3,827,704
7,537,484
8,147,756
Finance expenses (income)
(147,319)
22,340
(188,387)
12,376
Loss/(gain) on finance lease receivable
-
-
149,690
(610,008)
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Other comprehensive income (loss)
Amount that may be reclassified to profit or loss
Foreign currency translation adjustment
(40,155)
576,178
1,810,299
188,905
Total comprehensive income
$388,984
$2,036,596
$3,445,484
$797,780
Income per common share
Basic income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Diluted income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Non-GAAP Financial Measures
This press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures including "Adjusted Gross Margin" and "Adjusted EBITDA" to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below:
Adjusted Gross Margin is defined as gross profit before operating expenses, plus depreciation and amortization included in cost of sales, plus inventory provision amounts.
Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment.
You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definitions of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing their utility.
The table below provides a reconciliation of gross profit before operating expenses under IFRS Accounting Standards in the consolidated financial statements to Adjusted Gross Margin for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that Adjusted Gross Margin is useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Gross profit
$4,139,506
$5,310,462
9,133,972
$8,158,999
Add: Depreciation and amortization
43,728
58,322
113,353
110,870
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Adjusted Gross Margin
4,183,234
6,043,650
9,132,680
8,751,964
Adjusted Gross Margin (%)
55%
72%
58%
67%
The table below provides a reconciliation of net income under IFRS Accounting Standards in the unaudited condensed consolidated interim financial statements to Adjusted EBITDA for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that these non-GAAP measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31
2025
2024
2025
2024
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Add: Finance expense (gains)
(147,319)
22,340
(188,387)
12,376
Add: Depreciation and amortization
233,621
247,756
490,746
487,950
Add: Stock based compensation
65,540
81,464
156,063
197,393
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Add: Impairment of intangible asset
-
101,577
-
176,025
Add: (Gain)/loss of finance lease receivable
-
-
149,690
(610,008)
Adjusted EBITDA
$580,981
$2,588,421
$2,128,650
$1,354,706
About Covalon
Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
(1)
See "Non-GAAP Measures" below, including for a reconciliation of the non-GAAP measures used in this release to the most comparable IFRS Accounting Standards measures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528594851/en/
Contacts
To learn more about Covalon, please contact:Investor Relations, Covalon Technologies Ltd.Email: investors@covalon.com Website: https://covalon.com/
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
6 minutes ago
- Yahoo
AMPHENOL CORPORATION ANNOUNCES PRICING OF EURO-DENOMINATED SENIOR NOTES OFFERING
WALLINGFORD, Conn., June 11, 2025--(BUSINESS WIRE)--Amphenol Corporation (NYSE: APH) (the "Company") announced today the pricing of its offering of €600 million aggregate principal amount of senior notes due 2032 (the "Euro Notes"). The Euro Notes will have an interest rate of 3.125% per annum. The closing of the offering of Euro Notes (the "Euro Notes Offering") is expected to occur on June 16, 2025, subject to the satisfaction of customary closing conditions. On June 9, 2025, the Company announced the pricing of its offering of $750 million aggregate principal amount of 4.375% senior notes due 2028 (the "USD Notes") by means of a separate prospectus supplement. The closing of the offering of the USD Notes (the "USD Notes Offering") is expected to occur on June 12, 2025, subject to the satisfaction of customary closing conditions. Neither the completion of the Euro Notes Offering nor the offering of the USD Notes is contingent on the completion of the other. Therefore, it is possible that the Euro Notes Offering is completed and the USD Notes Offering is not completed. The Company intends to use the net proceeds from the Euro Notes Offering and the USD Notes Offering to repay borrowings under the Company's U.S. commercial paper program and for general corporate purposes. BNP PARIBAS, Citigroup Global Markets Limited and Commerzbank Aktiengesellschaft are serving as the joint book-running managers for the Euro Notes Offering. The Euro Notes are being offered pursuant to the Company's effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of this offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus for the offering may be obtained from BNP PARIBAS toll-free at 1-800-854-5674, Citigroup Global Markets Limited toll-free at 1-800-831-9146 and Commerzbank Aktiengesellschaft toll-free at 1-800-233-9164. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Euro Notes, nor will there be any sale of the Euro Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, solicitation or sale of the Euro Notes will be made only by means of the prospectus supplement and the accompanying prospectus. About AmphenolAmphenol Corporation is one of the world's largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable. Amphenol designs, manufactures and assembles its products at facilities in approximately 40 countries around the world and sells its products through its own global sales force, independent representatives and a global network of electronics distributors. Amphenol has a diversified presence as a leader in high-growth areas of the interconnect market including: Automotive, Commercial Aerospace, Communications Networks, Defense, Industrial, Information Technology and Data Communications and Mobile Devices. For more information, visit Forward-Looking StatementsStatements in this press release which are other than historical facts are intended to be "forward-looking statements" within the meaning of the Securities Exchange Act of 1934, as amended, the Private Securities Litigation Reform Act of 1995 and other related laws. While the Company believes such statements are reasonable, the actual results and effects could differ materially from those currently anticipated. Details regarding various significant risks and uncertainties that may affect our operating and financial performance can be found in the Company's latest Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. In providing forward-looking statements, the Company is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. Prohibition of Sales to EEA Retail InvestorsThe Euro Notes are not intended to be offered, sold or otherwise made available, and should not be offered, sold or otherwise made available, to any retail investor in the European Economic Area (the "EEA"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of MiFID II; (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended, the "Insurance Distribution Directive"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (as amended, the "Prospectus Regulation"). Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the Euro Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Euro Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. United KingdomThe communication of this announcement, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and any other document or materials relating to the issue of the Euro Notes is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom's Financial Services and Markets Act 2000 (as amended, the "FSMA"). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom ("UK"). The communication of such documents and/or materials is only being made to (i) persons outside the UK; (ii) and those persons in the UK (A) who have professional experience in matters relating to investments who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order")); or (B) who are high net worth companies, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Financial Promotion Order, (all such persons together being referred to as "relevant persons"). In the UK, this announcement, the prospectus supplement, the accompanying prospectus and the Euro Notes offered hereby are only available to, and any investment or investment activity to which this announcement, the prospectus supplement, the accompanying prospectus, any related free writing prospectus or any other document or materials relating to the issue of the Euro Notes relates will be engaged in only with, relevant persons. Any person in the UK that is not a relevant person should not act or rely on this announcement, the prospectus supplement, the accompanying prospectus, any related free writing prospectus or any other document or materials relating to the issue of the Euro Notes or any of their contents. Prohibition of Sales to UK Retail InvestorsThe Euro Notes are not intended to be offered, sold or otherwise made available, and should not be offered, sold or otherwise made available, to any retail investor in the UK. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended, the "EUWA"); (ii) a customer within the meaning of the provisions of FSMA and any rules or regulations made under the FSMA to implement the Insurance Distribution Directive, where that customer would not qualify as a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of the Prospectus Regulation as it forms part of domestic law by virtue of the EUWA (the "UK Prospectus Regulation"). Consequently, no key information document required by the PRIIPs Regulation as it forms part of domestic law by virtue of the EUWA (the "UK PRIIPs Regulation") for offering or selling the Euro Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the Euro Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. UK MIFIR product governance / Professional Investors and ECPs Only Target MarketSolely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Euro Notes has led to the conclusion that: (i) the target market for the Euro Notes is only eligible counterparties as defined in the FCA Handbook Conduct of Business Sourcebook ("COBS"), and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MiFIR"); and (ii) all channels for distribution of the Euro Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Euro Notes (a "distributor") should take into consideration the manufacturers' target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK MiFIR Product Governance Rules") is responsible for undertaking its own target market assessment in respect of the Euro Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels. View source version on Contacts Sherri ScribnerVice President, Strategy and Investor Relations203-265-8820IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
70% of U.S. Workers Want Robots To Help
Survey of 1,000 employees in the US MUNICH, June 11, 2025--(BUSINESS WIRE)--US workers welcome robot technology in the workplace: About 70% think that robots help manufacturers to deal with the lack of factory workers ensuring competitiveness. Two-thirds believe the use of robots will help to bring industrial production back home. These are findings of the automatica Trend Index 2025. The study surveyed 1,000 employees in the US on behalf of automatica, the world´s leading trade fair for robotics and automation (24-27 June in Munich, Germany). The US government is actively working to bring industrial production back to the United States. As the world's most advanced manufacturing countries have shown, robots are the key to integrating automation into a factory: China has more than doubled the ratio of robots to factory workers in four years (2018-2022), and now ranks third in the world. Robot density in China reached 470 robots per 10,000 workers in 2023, compared to 295 units in the United States, which ranks tenth, according to the International Federation of Robotics. 2.1 million unfilled jobs The push for automation technology is strongly driven by labor shortages. The Manufacturing Institute (MI) predicts that nearly 2.1 million manufacturing jobs will go unfilled by 2030 due to a lack of skilled workers. The automatica trend index shows that US workers welcome robots to take over dirty, dull and dangerous tasks: A strong majority of 75% believe that robots reduce the risk of injury to humans by performing tasks such as heavy lifting. 73% see robots as an important solution for handling hazardous materials. 65% say robots will assist workers, allowing older people to stay in work longer. "Showing how robots can take over repetitive or dangerous tasks, while allowing workers to focus on higher-value jobs, is important for the successful integration of robotics into a factory workforce," says Patrick Schwarzkopf, advisory board member of automatica at Messe München in Germany. "Driven by a number of technological innovations such as artificial intelligence, easy-to-use programming or cost-saving efficiency, industrial robotics is becoming more accessible to companies than ever before. This will be demonstrated at the world's leading trade fair for intelligent automation and robotics 'automatica 2025' from June 24 to 27 in Munich, Germany. FULL TEXT press release at: About automaticahttps:// View source version on Contacts econNEWSnetworkCarsten HeerTel. +49 40 82244284newsroom@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Community Healthcare Trust Releases 2024 Corporate Sustainability Report
FRANKLIN, Tenn., June 11, 2025 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) (the "Company") today announced the release of its second Corporate Sustainability Report highlighting the Company's progress and its sustainability initiatives implemented in 2024. The report is aligned with the Global Reporting Framework Initiative (GRI) and can be found on the Corporate Responsibility page of the Company's Investor Relations section of its website at "From reducing our environmental impact to strengthening our culture of accountability, we are committed to progress that is both meaningful and measurable," said David H. Dupuy, President and Chief Executive Officer of Community Healthcare Trust Incorporated. "This report is not only a reflection of our progress but a reaffirmation of our commitment to transparency and continuous improvement." Key Highlights of the Report: Sustainability initiatives implemented in our corporate office and real estate portfolio Environmental performance of our corporate office and real estate portfolio Progress toward our 2030 environmental targets Climate risk and resiliency policies to identify and manage climate risks Employee, tenant, and community engagement programs Governance practices to ensure transparency, accountability, and ethical conduct About Community Healthcare Trust Incorporated Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in our target sub-markets throughout the United States. Cautionary Note Regarding Forward-Looking StatementsIn addition to the historical information contained within, the matters discussed in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "believes", "expects", "may", "will," "should", "seeks", "approximately", "intends", "plans", "estimates", "anticipates" or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of Community Healthcare Trust Incorporated (the "Company"). Thus, the Company's actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company's common stock, changes in the Company's business strategy, availability, terms and deployment of capital, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company's competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, changes in interest rates, supply chain disruptions, labor conditions, tariffs and global trade tensions, and/or the conflicts in Ukraine and the Middle East, and the other factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this press release and undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law. CONTACT Bill Monroe, 615-771-3052 View original content: SOURCE Community Healthcare Trust Incorporated Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data